CJC-1295 / Ipamorelin

01 What is CJC-1295 / Ipamorelin?

CJC-1295/Ipamorelin is arguably the most popular peptide combination in the entire biohacking and anti-ageing clinic space. It pairs a GHRH analogue (CJC-1295) with a GHRP (Ipamorelin) to produce synergistic growth hormone release — meaning the combined effect is significantly greater than either peptide alone. The logic is elegant: GHRH (Growth Hormone Releasing Hormone) tells your pituitary to make more GH. GHRP (Growth Hormone Releasing Peptide) tells your pituitary to release what it has made. Using both simultaneously is like pressing the accelerator and releasing the brake at the same time — you get a much larger, more physiological GH pulse. CJC-1295 comes in two forms: with DAC (Drug Affinity Complex), which extends the half-life to 6-8 days creating a sustained GH elevation, and without DAC (also called Mod GRF 1-29), which has a short half-life and produces discrete GH pulses. Most clinics prefer the no-DAC version because it better mimics your body's natural pulsatile GH release pattern. Ipamorelin was chosen for this stack because it is the cleanest GHRP available — minimal appetite stimulation (unlike GHRP-6), no cortisol or prolactin elevation (unlike GHRP-2 or Hexarelin), and no desensitisation with long-term use. It is the gentlest way to trigger GH release.

02 How Does It Work?

CJC-1295 (Mod GRF 1-29) binds the GHRH receptor on pituitary somatotrophs, stimulating GH synthesis and priming the cells for release. The modified amino acid sequence (positions 2, 8, 15, 27) protects against enzymatic degradation, extending the half-life to approximately 30 minutes (vs 7 minutes for native GHRH). Ipamorelin binds the GHS-R (ghrelin receptor) on pituitary somatotrophs, triggering immediate GH release. Unlike other GHRPs, Ipamorelin shows high selectivity for GH release with minimal effects on cortisol, prolactin, or appetite. The GH pulse peaks at 30-45 minutes post-injection. Combined: CJC-1295 amplifies the GH synthesis and Ipamorelin triggers the release. Studies show the combination produces 3-5x more GH than either peptide alone. The GH pulse mimics natural physiology — a sharp peak followed by return to baseline — which is considered safer than the sustained elevation produced by synthetic HGH or CJC-1295 with DAC.

03 What Does The Research Say?

Individual peptide research is solid: CJC-1295 (with DAC): Phase II clinical trial showed sustained 2-3x elevation of IGF-1 over 2-4 weeks with weekly dosing. Well-tolerated. No serious adverse events. Ipamorelin: Studied in multiple contexts including post-surgical recovery. Clean GH release profile confirmed in human studies. No desensitisation observed over 12-week protocols. The combination: widely used in anti-ageing clinics with consistent clinical outcomes — improved sleep quality (deeper stage 3/4 sleep), enhanced recovery from exercise, improved skin quality, modest fat loss, and improved body composition over 3-6 month protocols. No large-scale, long-term RCTs exist for the combination specifically. Evidence is a combination of individual peptide trials and extensive clinical practice data from anti-ageing medicine.

04 Reported Dosages

Most common clinic protocol: CJC-1295 no DAC (Mod GRF 1-29): 100mcg Ipamorelin: 100-200mcg Combined subcutaneous injection, typically at bedtime (to amplify the natural nocturnal GH pulse). Frequency: Daily (5 days on, 2 days off) or daily for 8-12 week cycles. Some protocols use twice daily (morning + bedtime) for more aggressive results. Always inject on an empty stomach — food (especially carbs and fats) blunts GH release. CJC-1295 with DAC: 2mg once weekly (less common, sustained elevation rather than pulsatile). DISCLAIMER: These are research peptides. Not approved for clinical use. Work with an experienced practitioner.

05 Side Effects & Risks

Ipamorelin is the cleanest GHRP — minimal appetite stimulation, no cortisol or prolactin elevation. CJC-1295 can cause facial flushing and a head rush immediately post-injection (lasting 5-10 minutes). Water retention is mild. Occasional tingling in extremities (GH effect). Vivid dreams are commonly reported (due to enhanced deep sleep). Long-term: theoretical concerns about sustained IGF-1 elevation and cancer risk apply to any GH-boosting protocol, though these peptides produce more moderate and physiological elevations than synthetic HGH. Regular blood monitoring (IGF-1, fasting glucose, HbA1c) is recommended.

06 Legal Status